WO1995033062A3 - Verfahren zum einbringen von fremdmaterial in höhere eukaryotische zellen - Google Patents

Verfahren zum einbringen von fremdmaterial in höhere eukaryotische zellen Download PDF

Info

Publication number
WO1995033062A3
WO1995033062A3 PCT/EP1995/001989 EP9501989W WO9533062A3 WO 1995033062 A3 WO1995033062 A3 WO 1995033062A3 EP 9501989 W EP9501989 W EP 9501989W WO 9533062 A3 WO9533062 A3 WO 9533062A3
Authority
WO
WIPO (PCT)
Prior art keywords
foreign matter
eukaryotic cells
higher eukaryotic
introducing foreign
dna
Prior art date
Application number
PCT/EP1995/001989
Other languages
English (en)
French (fr)
Other versions
WO1995033062A2 (de
Inventor
Matthew Cotten
Adam Baker
Suzanna Chiocca
Original Assignee
Boehringer Ingelheim Int
Matthew Cotten
Adam Baker
Suzanna Chiocca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4418825A external-priority patent/DE4418825A1/de
Priority claimed from DE19944442587 external-priority patent/DE4442587A1/de
Application filed by Boehringer Ingelheim Int, Matthew Cotten, Adam Baker, Suzanna Chiocca filed Critical Boehringer Ingelheim Int
Priority to AU26160/95A priority Critical patent/AU709148B2/en
Priority to JP8500282A priority patent/JPH10500578A/ja
Priority to MX9605941A priority patent/MX9605941A/es
Priority to EP95920887A priority patent/EP0767840A2/de
Priority to US08/750,180 priority patent/US6284880B1/en
Publication of WO1995033062A2 publication Critical patent/WO1995033062A2/de
Publication of WO1995033062A3 publication Critical patent/WO1995033062A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Den beim Einbringen von Fremdmaterial in höhere eukaryotische Zellen, insbesondere bei der Transfektion mit DNA, auftretenden Toxizitätsproblemen wird begegnet, indem in der Zelle Genprodukte zur Expression gebracht werden, die die durch den Transfektionsprozeß ausgelöste Apoptose blockieren und/oder indem die Zellen mit anti-inflammatorischen Substanzen behandelt werden. Bevorzugt werden als anti-Apoptose-Gene Bcl-2, E1B 19K oder ein anti-apoptotisch wirksames Gen vom Hühner-Adenovirus CELO, als anti-inflammatorisch wirkende Substanz Adenovirus VA1, das in Form von VA1-DNA in die Zelle eingebracht wird, verwendet. Mit Hilfe dieser Maßnahmen kann eine lang anhaltende Genexpression erzielt werden.
PCT/EP1995/001989 1994-05-30 1995-05-26 Verfahren zum einbringen von fremdmaterial in höhere eukaryotische zellen WO1995033062A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU26160/95A AU709148B2 (en) 1994-05-30 1995-05-26 Method for introducing foreign matter into higher eukaryotic cells
JP8500282A JPH10500578A (ja) 1994-05-30 1995-05-26 外来物質を高等真核生物細胞に導入する方法
MX9605941A MX9605941A (es) 1994-05-30 1995-05-26 Procedimiento para introducir material extraño en celulas eucarioticas superiores.
EP95920887A EP0767840A2 (de) 1994-05-30 1995-05-26 Verfahren zum einbringen von fremdmaterial in höhere eukaryotische zellen
US08/750,180 US6284880B1 (en) 1994-05-30 1995-05-26 Chicken embryo lethal orphan (CELO) virus GAM-1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DEP4418825.0 1994-05-30
DE4418825A DE4418825A1 (de) 1994-05-30 1994-05-30 Verfahren zum Einbringen von Fremdmaterial in höhere eukaryotische Zellen
DEP4442587.2 1994-11-30
DE19944442587 DE4442587A1 (de) 1994-11-30 1994-11-30 Verfahren zum Einbringen von Fremdmaterial in höhere eukaryotische Zellen

Publications (2)

Publication Number Publication Date
WO1995033062A2 WO1995033062A2 (de) 1995-12-07
WO1995033062A3 true WO1995033062A3 (de) 1996-07-18

Family

ID=25937004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/001989 WO1995033062A2 (de) 1994-05-30 1995-05-26 Verfahren zum einbringen von fremdmaterial in höhere eukaryotische zellen

Country Status (8)

Country Link
US (2) US6284880B1 (de)
EP (1) EP0767840A2 (de)
JP (1) JPH10500578A (de)
AU (1) AU709148B2 (de)
CA (1) CA2190963A1 (de)
CO (1) CO4410254A1 (de)
MX (1) MX9605941A (de)
WO (1) WO1995033062A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615803A1 (de) 1996-04-20 1997-10-23 Boehringer Ingelheim Int CELO-Virus
CA2304131A1 (en) * 1997-09-19 1999-04-01 James M. Wilson Method for gene transfer using bcl2 and compositions useful therein
WO1999041398A1 (en) * 1998-02-11 1999-08-19 Genvec, Inc. Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
US7033673B2 (en) * 2003-07-25 2006-04-25 Analytical Services & Materials, Inc. Erosion-resistant silicone coatings for protection of fluid-handling parts
US20070178137A1 (en) * 2006-02-01 2007-08-02 Toby Freyman Local control of inflammation
US20110189734A1 (en) * 2007-08-14 2011-08-04 Taylor Alexander H Novel methods and cell lines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007283A1 (de) * 1991-09-30 1993-04-15 Boehringer Ingelheim International Gmbh Zusammensetzung für das einbringen von nukleinsäure-komplexen in höhere eukaryotische zellen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007283A1 (de) * 1991-09-30 1993-04-15 Boehringer Ingelheim International Gmbh Zusammensetzung für das einbringen von nukleinsäure-komplexen in höhere eukaryotische zellen

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHIOU, S.-K. ET AL.: "Functional Complementation of the Adenovirus E1B 19-Kilodalton Protein with Bcl-2 in the Inhibition of Apoptosis in Infected Cells", J.VIROLOGY, vol. 68, no. 10, October 1994 (1994-10-01), pages 6553 - 6566, XP002003026 *
CURIEL, D.T. ET AL.: "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes", HUMAN GENE THERAPY, vol. 3, 1992, pages 147 - 154, XP002003028 *
DATABASE EMBL "Fowl adenovirus 1 DNA fragment", XP002003029, retrieved from EBI *
DEBBAS, M. UND WHITE, E.: "Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B", GENES & DEVELOPMENT, vol. 7, 1993, pages 546 - 554, XP002003024 *
MIYASHITA, T. UND REED, J.C.: "bcl-2 Gene Transfer Increases Relative Resistance of S49.1 and WEHI7.2 Lymphoid Cells to Cell Death and DNA Fragmentation Induced by Glucocorticoids and Multiple Chemotherapeutic Drugs", CANCER RESEARCH, vol. 52, October 1992 (1992-10-01), pages 5407 - 5411, XP002003025 *
RAO, L. ET AL.: "The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins", PROC.NATL.ACAD.SCI.USA, vol. 89, August 1992 (1992-08-01), pages 7742 - 7746, XP002003023 *
ZATLOUKAL, K. ET AL.: "Transferrinfection: A Highly Efficient Way to Express Gene Constructs in Eukaryotic Cells", ANNALS NEW YORK ACADEMY OF SCIENCES, vol. 660, 1992, pages 136 - 153, XP002003027 *

Also Published As

Publication number Publication date
AU709148B2 (en) 1999-08-19
EP0767840A2 (de) 1997-04-16
JPH10500578A (ja) 1998-01-20
AU2616095A (en) 1995-12-21
CA2190963A1 (en) 1995-12-07
CO4410254A1 (es) 1997-01-09
US6284880B1 (en) 2001-09-04
WO1995033062A2 (de) 1995-12-07
MX9605941A (es) 1997-12-31
US20020049313A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
GEP20012559B (en) Complementary Adenoviral Vector Systems and Cells Lines
DE69731611D1 (de) Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor
AU4882296A (en) DNA molecules, preparation and use in gene therapy
AU5957986A (en) Vector for the expression of gamma-interferon in mammal cells, method for its implementation, product obtained and pharmaceutical composition containing the gamma-interferon
NO964445L (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
WO1995027071A3 (en) An adenovirus supervector system
CA2228635A1 (en) Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
JPS57500830A (de)
EP0281547A3 (en) Apparatus for the culture of microorganisms in the dormant state, particularly filamentous microorganisms
Toscani et al. Sodium butyrate in combination with insulin or dexamethasone can terminally differentiate actively proliferating Swiss 3T3 cells into adipocytes.
IL148152A0 (en) Sequence-specific dna recombination in eukaryotic cells
EP1396548A3 (de) Nukleinsäuremutationserkennung in histologischem Gewebe
AUPN477695A0 (en) Gene therapy
WO1995033062A3 (de) Verfahren zum einbringen von fremdmaterial in höhere eukaryotische zellen
DE69333529D1 (de) Pflanzenvirus-vektor, plasmid, methode der expression fremder gene und methode zur gewinnung obiger genprodukte
IE56720B1 (en) Methods and compositions for expression of competent eukaryotic gene products
TW358121B (en) Method for extracting useful substance from culture medium containing mycelium
DK0567560T3 (da) Fremgangsmåde til kontinuerlig disintegration og/eller tørring af materialer, såsom pasta, slam, pre ssekage, filterkage eller lignende, især fribrøse materialer samt apparat til udøvelse af fremgangs måden
NO981322D0 (no) Farmasöytiske preparater for bruk ved nukleinsyretransfeksjon, og deres anvendelse
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
Ganguly et al. A cell-free assay using cytoplasmic cell extracts to study rejoining of radiation-induced DNA double-strand breaks in human cell nuclei
AU634575B2 (en) Rna with endoribonuclease activity for mrna of ripening genes, the preparation thereof and the use thereof in plants
AU6113098A (en) Compositions for treatment of disorders involving programmed cell death
Quillardet et al. Damaged-site independent mutagenesis of phage λ produced by inducible error-prone repair
Cotten et al. Chicken embryo lethal orphan(CELO) virus GAM-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP KR MX PL RU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: THE CODE IDENTIFYING THE KIND OF DOCUMENT TO WHICH THE PAMPHLET RELATES SHOULD READ"A3"INSTEAD OF "A2"

WWE Wipo information: entry into national phase

Ref document number: 2190963

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1996/005941

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1995920887

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08750180

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995920887

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995920887

Country of ref document: EP